Easier-To-Produce Room Temperature Covid Shot Shows Promise In Early Clinical Trials

A protein-based Covid-19 vaccine by Akston Biosciences that can be stored at room temperature and efficiently manufactured using existing technology was well-tolerated and provoked an immune response in all those receiving higher doses, according to data from an early-stage clinical trial, as the company vies to expand vaccine access around the world. The early-stage clinical trial, published in the medical journal Vaccine, tested the shot in 60 healthy adults ages 18 to 65 years in the Netherlands, who received one or two 22.5µg, 45µg or 90µg doses 28 days apart. Akston said the vaccine was “well-tolerated” and had mild side effects comparable to those of approved vaccines, including headache and injection site pain. Read more >>